60 Degrees Pharmaceuticals awarded Canadian patent for tafenoquine

60 Degrees Pharmaceuticals announced that the Canadian Intellectual Property Office has issued the Company a patent covering the use of novel regimens of tafenoquine for the prevention of malaria in malaria-naive individuals. Travelers from, and residents of, Canada and the United States, are usually malaria naive because they have not previously contracted malaria and thus lack immunity to the disease. Tafenoquine is the active molecule in the Company’s U.S. Food and Drug Administration-approved regimen for malaria prevention, ARAKODA. ARAKODA, an oral tablet containing 100 mg of tafenoquine base, is an anti-malarial indicated in the U.S. for the prophylaxis of malaria in individuals aged 18 years and older. Travelers or individuals at risk of contracting malaria are prescribed 2 x 100 mg tablets once per day for three days prior to travel, 2 x 100 mg tablets weekly for up to six months during travel, then 2 x 100 mg in the week following travel. ARAKODA is not approved by Health Canada for the prevention of malaria. The newly issued Canadian patent provides exclusive use of tafenoquine for preventing malaria in malaria-naive patients in Canada to December 2, 2035. The Company was previously issued a U.S. patent covering the use of tafenoquine for malaria prevention in malaria-naive individuals. The U.S. and Canadian patents cover the ARAKODA dosing regimen approved in the U.S. for malaria prevention.